Allergan 1st-qtr earnings beat expectations, but sales miss

10 May 2016

Shares Ireland-incorporated drugmaker Allergan (Nasdaq: AGN) were up 5.9% at $226.29 mid-morning, after the company posted first-quarter 2016 earnings results that beat analysts’ expectations and announced a share buyback program of up to $10 billion.

Allergan reported net income attributable to ordinary shareholders of $186.1 million, or earnings per share of $0.47, compared with a loss of $535.2 million, or $1.85 per share, in the like year-earlier period. Excluding special items, the company earned $3.04 per share, slightly above the average analysts' estimate of $3.01, according to Thomson Reuters.

Allergan, the subject of an abandoned $160 billion tax inversion-based takeover by Pfizer and in the process of selling its generics business to Israel’s Teva, reported a loss from continuing operations of $81.7 million, or a loss of $0.38 a share in the quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK